Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia
8-Year Follow-Up on MINDACT Trial for Adjuvant Chemo in HR+/HER2- BC: Do Genomically Low-Risk Tumors Benefit From Chemo? Is DMFS Improved?
Login to view comments.
Click here to Login
2021